Lawsuit Help Desk

Xeljanz Lawsuits and Settlements

Were you or a loved one prescribed Xeljanz?

Did you later suffer from major cardiac events (such as a heart attack or a stroke) while on the drug? Or a pulmonary embolism, deep vein thrombosis or blood clot one a month of taking the drug? Then there is a real likelihood you would qualify for an Xeljanz lawsuit and settlement opportunity. 

Then you likely qualify for an Xeljanz lawsuit and settlement opportunity.

Will your leading mass torts
firms take my case?

Contact us to find out (We’ll get back to you the same day)

"*" indicates required fields

I represent, understand and agree that: 1) I am 18 years of age or older; 2) I have read and agree to’s Terms of Service, Privacy Policy, that the representations here are Paid Attorney Advertising, and additional legal disclaimers herein (if any); 3) submitting this form does not create an attorney-client relationship; 4) I am not already represented by an attorney for this matter; and 5) I consent to be contacted under the Terms and Conditions of Contact in order to discuss my legal options, so that I may obtain legal representation.

Why Are Xeljanz Lawsuits Being Filed?

The Xeljanz lawsuits are being filed against Pfizer for its failure to warn of the risks associated with using Xeljanz, including serious and fatal side effects. Xeljanz (tofacitinib) has been prescribed to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and polyarticular course juvenile idiopathic arthritis. 

Patients taking the medication have developed blood clots, heart attacks, strokes, and even cancer. Life-threatening infections and weakened immune systems rendering vulnerability to infections have also been reported. 

A number of the lawsuits allege that Pfizer misrepresented or omitted safety information regarding the drug in order to market it more aggressively. Patients have experienced severe medical complications, and plaintiffs have alleged these could have been avoided had they been made aware of the drug’s risks. 

Furthermore, the lawsuits claim that not only did Pfizer fail to warn patients adequately but it also actively tried to downplay or hide the risks associated with Xeljanz. The FDA issued a Black Box Warning for Xeljanz in 2019, but it is estimated hundreds of thousands have taken the drug before the warning was issued.  

Xeljanz (tofacitinib) is a prescription medication manufactured by Pfizer. The drug used to treat certain autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It belongs to the class of Janus kinase (JAKs) inhibitors. These drugs work by inhibiting Janus kinases, enzymes involved in the immune response, and thereby reduce inflammation and improve symptoms in patients with these conditions.

For those with rheumatoid arthritis, Xeljanz may be prescribed as an alternative when other treatments have not been effective or have caused unacceptable side effects. It can be taken alone or in combination with methotrexate. Patients with psoriatic arthritis may also benefit from Xeljanz when other treatments are not working or causing side effects, either alone or with other medications such as methotrexate. Xeljanz may also be used to induce and maintain remission in adults with moderate to severe ulcerative colitis that has not responded well to other treatments.

It is important, however, to note that Xeljanz can increase the risk of serious infections, including tuberculosis and certain types of cancers, so patients should be monitored closely for signs of infection and seek medical attention if they experience fever, cough, or difficulty breathing. Dangerous cardiovascular complications have also been found, causing numerous lawsuits by injured victims. 

In 2012, the U.S. Food and Drug Administration (FDA) approved tofacitinib, the active ingredient of Xeljanz, for use in adults with rheumatoid arthritis who had failed to respond adequately to methotrexate therapy. Then, in 2017, the FDA also approved tofacitinib for use in adults with psoriatic arthritis who had failed to respond adequately to other medications. Finally, in 2018, tofacitinib was approved by the FDA as a treatment option for adults with ulcerative colitis who had similarly not responded well to other therapies. It is estimated some 130,000 people in the United States have been prescribed Xeljanz from its 2012 FDA approval to 2018. 

The Xeljanz producer, Pfizer, was mandated by the FDA to conduct out a lengthy post-market research study in 2012. The study was to assess the risk of cancer, major cardiovascular events, and infections linked to the usage. Initial clinical studies revealed questions regarding its safety, particularly at higher doses, prompting the request for the investigation.

More than 4,800 rheumatoid arthritis patients who have taken at least one dosage of Xeljanz participated in the post-market study, also known as the ORAL Surveillance study. In order to evaluate the drug’s long-term safety, patients were monitored for up to 9 years.

The FDA revealed the ORAL Surveillance study’s final findings in February 2021. In comparison to patients receiving a TNF inhibitor, another type of medicine used to treat rheumatoid arthritis, the study found that patients taking Xeljanz at the recommended dose of 5 mg twice day did not have an elevated risk of cardiovascular events or cancer. In comparison to those on a TNF inhibitor, patients using Xeljanz at a higher dose of 10 mg twice daily had an elevated risk of both cardiovascular events and cancer, according to the ORAL Surveillance trial. The study also demonstrated that, in comparison to a TNF inhibitor, Xeljanz carries a higher risk of severe infections such TB and herpes zoster (shingles). The FDA updated the prescription instructions for Xeljanz to add a warning regarding the elevated risk of cancer and cardiovascular events with this medication’s higher dose in response to the study’s findings. Healthcare professionals were also urged to strictly adhere to approved dosing guidelines when prescribing Xeljanz and to keep an eye out for symptoms of infection, such as shingles and tuberculosis.

The long-term post-market research study for Xeljanz concluded that at the recommended dose of 5 mg twice daily, the medication is generally safe and effective for the treatment of rheumatoid arthritis. The higher 10 mg dosage twice daily was also associated with an increased risk of serious infections, cardiovascular complications, as well as cancer, according to the study.

In February 2019, the FDA issued a warning for Xeljanz (tofacitinib) due to an increased risk of blood clots and death when taken at higher doses than recommended in patients with ulcerative colitis. The findings were based on interim results from a clinical trial involving Xeljanz for ulcerative colitis which found that those taking the 10 mg twice daily dose had a greater chance of developing blood clots compared to those taking the lower 5 mg dose or placebo, in addition to having more deaths recorded. Here, the FDA reported 19 cases of pulmonary blood clots in patients who received Xeljanz 10 mg twice-daily, compared to only three in those taking TNF blockers. Furthermore, 45 patient deaths were been reported among those on the Xeljanz regimen, compared with 25 fatalities among those taking TNF blockers. This evidence is highly concerning and warrants further investigation.

In July of 2019, the FDA approved a Black Box warning. It alerted patients and healthcare providers of the increased risk of blood clots and death associated with twice-daily doses of 10 mg each. The highest risk was observed among those with rheumatoid arthritis who were 50 years or older and had at least one cardiovascular risk factor. Prior to this addition on July 2019, there had been no warnings regarding thrombotic events linked to Xeljanz. Black Box warnings are the most severe warnings issued by the FDA, appearing prominently on the medication labeling and alerting both healthcare providers and patients to life-threatening risks associated with usage. 

Pfizer updated the labeling for Xeljanz in July 2019 to include a boxed warning that details an increased risk of sudden cardiovascular-related mortality. The warning stated that taking 10mg of Xeljanz twice day increased the risk of sudden cardiovascular fatalities in rheumatoid arthritis patients 50 years of age and older.

Following the warning, the FDA advised healthcare providers to prescribe Xeljanz at the lowest effective dose and for the shortest possible time in those with ulcerative colitis. Patients taking Xeljanz were similarly instructed to seek medical attention right away if experiencing symptoms such as sudden shortness of breath, chest pain, or leg swelling.

As a result of this warning, there has been an increased awareness surrounding the potential risks associated with Xeljanz use and greater caution among both healthcare providers when prescribing it and patients in monitoring any side effects or symptoms. Consequently, prescriptions for Xeljanz have decreased but it remains an important treatment option for certain individuals suffering from rheumatoid arthritis and psoriatic arthritis.

The black box warning for Xeljanz is a reminder of the importance of ongoing safety monitoring and informed decision making when it comes to any medication. Healthcare providers and patients need to carefully consider the risks and benefits before starting treatment.

Furthermore, regardless of the FDA’s activity, pharmaceutical businesses are legally obligated to provide reasonable disclosures of any possible dangers related to using their drugs. When prescribing medications to their patients, doctors rely on these disclosures to provide them the information they need to decide for themselves whether or not to take the prescription. However, because doing so would hurt their earnings, pharmaceutical corporations frequently attempt to avoid making these required disclosures. In order for clinicians and patients to have access to the most accurate information feasible before making a health-related choice, such disclosure must be given.

Recent studies have shown a higher mortality rate and risk of serious side effects in people taking Xeljanz, especially those with cancers. The most common Xeljanz side effects include severe infections, lymphoma, and other cancers. According to the FDA, Xeljanz also increases the risk for severe congestive heart failure, thromboembolic events (blood clots in the lungs), or hepatitis B reactivation in some patients. In addition to the mortality rate and side effects of Xeljanz, there is also evidence that suggests the drug causes an increased risk for serious gastrointestinal side effects. This includes severe abdominal pain, ulcers, and other problems in the digestive system. Research has also shown that Xeljanz causes dangerously high levels of liver enzymes. Blood clots that can form in a person’s legs include PE and DVT. Blood clots can be dangerous on their own, but the major risk arises when they become large enough to separate in the body and spread to other organs. When a blood clot occurs in PE or PVT, it moves to the lungs and gets trapped in an artery, obstructing the flow of blood and oxygen. If a person does not get medical attention very far away, this creates a condition that could be lethal.

Over the following few months, the FDA continued to look into the negative effects of Xeljanz, but it wasn’t long before another statement was made. The FDA approved a black box warning for Xeljanz in July, which is toughest U.S. warning on a medicine label. Black box warnings are only given to drugs when there is solid proof that they are linked to serious, irreversible side effects. The Xeljanz inquiry has undergone several updates, and this is most likely not the last.

Research suggests that Xeljanz increases the risk of certain serious health complications, including cancer, major cardiac events (including heart attacks and strokes), and blood clot complications (including pulmonary embolisms and deep vein thrombosis). According to the U.S. Food and Drug Administration (FDA), studies conducted on those prescribed Xeljanz showed an increased risk of death due to serious infections, malignancies, and cardiovascular events. Additionally, researchers have found that those taking Xeljanz are at a greater risk for developing blood clots and deep vein thrombosis (DVT). The FDA issued multiple warnings concerning the use of Xeljanz and advised healthcare providers to use caution when prescribing this medication. Despite the risks associated with Xeljanz, Pfizer failed to warn consumers and the medical community of these side effects. 

The number of Xeljanz lawsuits is estimated in the thousands, filed in both federal and state courts across the United States. Plaintiffs are alleging that Pfizer, the drug’s manufacturer, was negligent in its duties by failing to conduct adequate safety research and testing prior to bringing Xeljanz to market, omitting vital information about serious health risks associated with higher doses of the drug, such as life-threatening blood clots and other severe health problems, and neglecting to warn patients that higher doses could potentially increase their risk of developing cardiovascular injuries.

Plaintiffs assert that they suffered serious side effects after taking Xeljanz including blood clots, heart attacks, strokes, pulmonary embolisms and vision loss, as well as lymphomas and other cancers, serious infections, extrapulmonary tuberculosis and liver damage. These allegations center around Pfizer’s negligence in failing to warn about the risks associated with taking Xeljanz and false or misleading marketing of the drug’s safety profile.

As with such serious injury cases, the Xeljanz plaintiffs seek damages for medical expenses, lost wages, emotional distress and physical pain and suffering. The lawsuits are still in their early stages and yet to be consolidated into a federal multidistrict litigation (MDL) or class action. However, given that thousands more are expected to be filed, it is increasingly likely that claims will eventually become centralized under an MDL or class action.

While the cases are quite early, Pfizer is expected to use the  federal preemption defense in the Xeljanz lawsuits. In other words, it is expected to argue that the FDA had approved the drug, and that since the Black Box warning, under federal law a manufacturer cannot on its own change the FDA-approved warning. However, our lawyers have indicated they believe argument will be unsuccessful in attempting to shield Pfizer. 

There are no inciteful reports of settlements in the numerous Xeljanz lawsuits filed to-date. This is true because the cases are in their infancy considering the recentness of the injuries incurred, as well as the FDA’s warnings. Our lawyers expect that as the cases are approaching many thousands, consolidation into a global MDL or class action become more likely, which will open up opportunities for global settlements.

The total settlement amount for individual cases of Xeljanz-related injuries will vary based on the severity of the injury and other factors. Generally, those with serious and permanent harm due to the drug may be eligible for higher compensation than those who experienced milder issues such as hospitalization or discomfort.

Medical product liability awards are typically proportional to the extent of damage inflicted. Pulmonary embolisms and other blood clot-related injuries usually carry a large dollar amount given their catastrophic consequences, including limb amputation and death in extreme situations. However, many sufferers may only experience hospital stay and several days of stress or unease.

Though it is impossible to give specific estimates without considering a case’s individual details, our lawyers approximate that the average settlement amount for Xeljanz lawsuits related to cardiovascular complications could range between $75,000 and $350,000. In more severe cases, where life-threatening or fatal injuries have occurred, settlements may reach millions of dollars.

How can I Tell if I Qualify for an Xeljanz Lawsuit?

If you took Xeljanz and experienced any of these complications, you should contact us: 

  • Major cardiovascular event (stroke, heart attack) requiring hospitalization while on the drug, or 
  • Pulmonary embolism (PE), deep vein thrombosis (DVT) or blood clot while on the drug or within one month of stopping usage. 

Our lawyers base their criteria on the medical research conducted, their understanding of the relevant courts involved, and rulings, settlements and verdicts are handed down, exactly what you’d expect from leaders in the field. Note that these criteria may change as these factors change. Please know that in the tragic case of resulting death, family members and next of kin are represented. Contact us now to find out more. 

man recovering in hospital who's filed an Xeljanz lawsuit
weighing the benefits of an Xeljanz lawsuit

What are my Legal Fees if Your Lawyers Take my Xeljanz Lawsuit?

We are pleased to inform you that if you meet the requirements, your legal representation will be provided on a contingent fee basis. This means that all legal costs and expenses associated with your case will be paid by our law firm, so you don’t have to worry about any out-of-pocket expenses. The fees and costs we incur in representing you will come directly out of any settlement or award amount you receive.

Unlike other mass torts sites, your case will be handled by experienced attorneys in this field instead of general personal injury lawyers referred by marketing firms. 

If for some reason the case is not won or settled, then you won’t owe anything as the risk has been assumed by our law firms.

What can I Recover from an Xeljanz Lawsuit?

Mass torts cases frequently provide very high dollar settlements, where each plaintiff receives as recovery in the hundreds of thousands or even millions of dollars. 

Having said that, we and our network of law firms have talked to thousands of injured. As we’ve heard time and again, and truly believe — there is no compensation that makes up for a serious injury or disease, period. 

But now that your family is dealing with the pain and suffering, through no fault of your own, you may be entitled to very significant financial compensation. 

To be specific, you would be entitled to recover past, present and future medical and mental health bills, as well as lost wages. Recovery dollars also compensate for non-economic losses, such as past, present and future pain and suffering, loss of consortium (companionship), and emotional distress. 

celebrating a an Xeljanz lawsuit settlement
lawyer counseling about *** lawsuit

If I'm Qualified for an Xeljanz Lawsuit, do I Have any Obligations to Lawsuit Help Desk? To your lawyers?

You have no obligations to us if you’re qualified. If we find that you are qualified, and you wish to proceed with the mass torts firms we have provided for you, the lawyers will discuss the retention agreement with you.

How Long do I Have to File my Xeljanz Lawsuit?

For yours and your family’s sake, act quickly, even if it’s not with us. Why? Statutes of limitations restrictions exacerbated by lagging scientific research may prevent your recovery. Also, if you file late, you may miss important settlement opportunities.  That’s why it’s very important to secure legal representation as soon as possible. In fact, one of our lawyers’ first actions for you will be to check your state’s statute of limitations and repose. 

State laws dictate the maximum length of time from an alleged offense that parties to a legal dispute have in order to file a lawsuit. These time limits are known as statutes of limitations (SOL) and statutes of repose (SOR). SOLs establish the maximum length of time for filing a lawsuit, and SORs end an individual’s right to sue after a certain amount of time even if no cause of action has been determined. In some cases, this means that those who caused harm may avoid being held accountable if medical research hasn’t linked their actions to specific illnesses or injuries before the SOR passes. Additionally, defendants could potentially be absolved from responsibility if an illness such as cancer has not yet begun before the SOR has expired.

We can help you understand your state’s SOL and SOR statues, so please reach out to us as soon as possible. Doing so will ensure that you don’t miss any opportunity to take legal action if applicable. Moreover, it is important to contact a lawyer before the statutes of limitations and repose expire in order to protect your rights. We look forward to hearing from you soon.

The challenge is that it may take years for medical research to establish the side effects of a drug. It may have taken this time for research to show a connection between the cause – the offending drug– and the patient’s symptoms. 

Also, manufacturers may be less than forthcoming regarding their clinical trials to protect sales, and sometimes actively promote misinformation. Meanwhile, the clock continues to tick on statutes of limitations and repose requiring lawsuits be filed within state-set limits. 

For Xeljanz, the drug was FDA approved in 2012, but it was not until 2019 that the FDA required a Black Box warning. In the interim, many thousands have been prescribed the drug for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and other ailments, who have experienced terrible side effects. The side effects range from pulmonary embolisms (PE), deep vein thrombosis (DVT), blood clots, heart attacks to liver damage and cancerous tumors.  

Manufacturers very often settle cases with thousands of defendants at a time; but in order to qualify as a recovery victim, your lawyer must have already filed your lawsuit. Contrary to urban myth, our lawyers have an obligation to the court to conduct their own due diligence – to see whose cases qualify based on leading medical research.

lawyers sprinting to file an Xeljanz lawsuit
client contacts lawyer about Xeljanz lawsuit

What are my Next Steps for Filing and Settling an Xeljanz Lawsuit?

If you or a loved one has been affected by Xeljanz, contact us today for a quick assessment of your case. Get peace of mind knowing that our experienced attorneys are here to help you.

Going forward, remember to save any documents that could serve as evidence in your case, including prescriptions, receipts, medical bills and reports, tests and diagnoses related to the usage of Xeljanz, and any other relevant documents.

Our attorneys can also reach out to doctors, labs, hospitals and pharmacists on your behalf if we take your case. When you get in touch with us, we will provide more information about how we can help you. Don’t wait – take action now!

The Lawsuit Help Desk Difference

Unlike most others, we do not act like third party middlemen – instead, we provide you immediate access to top 1%, nationally renowned mass torts attorneys, with deep knowledge in Xeljanz litigation. It is these leading lawyers who decide whether your case has merit. We will be forthright and honest with you.

Our mission is to inform the public, and provide direct access to leaders in the world of mass torts. 

We are not that annoying call center. We will respect your time. We will not hand you off, or give you the run around. 

We do not consider ourselves a marketing firm. Do not expect robocalls from us. If you’re emailed, it’s just to provide you helpful information, such as case status and ongoing research; you will not get spammy emails. We are here to help, not badger you.

A key distinction is that we have active attorneys and litigators on our staff. Do you really want advice about a mass tort that’s devastated your loved one’s lives — where settlements in the hundreds of thousands and millions are common — from a marketing or social media expert, a lifestyle coach, a psychologist or an influencer? In other words, we are not parroting talking points: We really know what we’re talking about. 

In fact, Lawsuit Help Desk was founded by Cameron Tousi, a leader in the world of complex litigation. He has received highest distinctions in peer reviews and awards from America’s leading legal publications. If you’d like to speak with Cameron, just let us know, and we’ll make it happen! 

Monthly Status Updates of Xeljanz Lawsuits

An important claim made by the plaintiffs in these claims is supported by a New England Journal of Medicine study: Xeljanz had a higher incidence of malignancy and adverse cardiovascular events than alternative treatment options.

Xeljanz lawsuits across the United States continue to mount. Reports from courts throughout the country show that more and more patients are filing claims against Pfizer affirming serious injuries linked to their use of Xeljanz. The majority of the claims affirm severe side effects such as stroke, pulmonary embolism and cardiovascular issues caused by the drug. 

The U.S. District Court for the Northern District of Ohio recently granted plaintiffs’ motion for class-action status in a lawsuit claiming Xeljanz increased their risk for developing cancer. This is a major development that could  result in hundreds or even thousands of additional claimants. 

In addition, the U.S. District Court for the Eastern District of Pennsylvania recently ruled that Xeljanz was defectively designed, stating that Pfizer should have warned doctors and patients about the  risks associated with long-term use. This decision could open the door to many more lawsuits against Pfizer. 

With courts across the country increasingly ruling in favor of plaintiffs and more class-action claims being filed, it is clear that the legal landscape surrounding Xeljanz is continuing to evolve.

In December 2022, Pfizer Inc., which manufactures and markets Xeljanz, filed a motion to dismiss several lawsuits affirming that use of its drug caused life-threatening medical conditions such as blood clots and pulmonary embolism. In response to this motion, plaintiffs’ lawyers argued that they had presented sufficient evidence to support their claims and requested additional discovery from Pfizer related to its marketing campaigns.

In December 2022, Pfizer also submitted a supplemental new drug application (sNDA) to the Food and Drug Administration (FDA), seeking approval to expand the label of Xeljanz to include treatment of ulcerative colitis. If approved, this would be the first such expanded use for the drug. 

In the month of December 2022, no additional Xeljanz lawsuits were filed. However, with the first case set to go to trial in April 2023 and Pfizer’s motion to dismiss several cases still pending, it is likely that more lawsuits will be filed in the coming months. The MDL hearings also prove pivotal for determining the scope of damages and whether or not these cases can be consolidated into a class action lawsuit.

There are over 5,000 cases that have been filed in federal court as of November 2022. Approximately 600 of these cases have already gone to trial or settled out-of-court. While the outcome is mixed across those individual trials, it can be reasonably assumed that many more cases end in settlements outside of court due to FDA warnings about  risks associated with taking Xeljanz long term. 

At this point, most experts agree that the odds are still slightly stacked in favor of the Xeljanz manufacturers. However, it is worth noting that recent court rulings have provided a much more favorable environment for plaintiffs to pursue their claims. 

The chance of a successful outcome in an individual case has become significantly higher in November 2022, as various studies and FDA warnings have combined to make the risks associated with taking Xeljanz very clear. This means that those considering legal action should get the advice of a qualified lawyer who can review their specific case and provide an honest assessment of its chances for success. 

It is also important to note that there are still many unanswered questions about how this litigation will be handled going forward into 2021 and beyond. Although it is impossible to predict exactly how things will unfold, it is clear that the chances of success for those pursuing legal action against the Xeljanz manufacturers is much greater than it was just a few months ago.

Xeljanz’s producer, Pfizer, has been the target of more than 1500 individual lawsuits since the controversy around it broke in 2019. According to these reports, using the medication has caused major side effects such pulmonary emboli, strokes, heart attacks, and other cardiovascular problems. Numerous states now permit combined litigation for claimants with identical claims as the number of lawsuits continues to rise.

Plaintiffs were still reporting significant side effects from taking Xeljanz in October 2022. Throughout the month, a number of fresh lawsuits have been submitted asserting that the medicine caused early death as a result of complications from a blood clot. Also, a number of class action lawsuits have been filed against Pfizer and other pharmaceutical firms alleging that they failed to sufficiently inform customers about the dangers of taking Xeljanz.

Many people who took Xeljanz and experienced adverse effects are still suing for money in October 2022 for their expenses and suffering. It will probably take some time for these lawsuits to be resolved, but it is obvious that there is still plenty to be litigated regarding this medication.

September 2022 has seen a decrease in Xeljanz lawsuits filed against the manufacturer Pfizer Inc. There were only six new cases reported this month, compared to fifteen in August and twenty-one in July. Of the six cases, two had been dismissed, while four remained pending. The four remaining cases involve different claimants who claim that they developed various forms of cancer due to their use of Xeljanz. 

A number of other lawsuits involving similar claims are currently at various stages throughout the legal system. In some instances, defendants have attempted to dismiss these suits based on a lack of evidence or a failure to adequately prove causation between Xeljanz and any medical issues that have occurred. However, plaintiffs argue that there is sufficient evidence to support their claims and that these dismissals are unjustified.

In a few instances, plaintiffs have successfully won cases involving Xeljanz by proving that the manufacturer had failed to adequately warn consumers of  risks associated with usage of the drug. In one such case, a jury awarded $2.75 million in damages to an individual who contracted cancer following her use of Xeljanz. 

The overall status of Xeljanz lawsuits remained largely unchanged in September 2022, with a slight decrease in new cases filed and existing suits making progress at various stages throughout the court system.

For Xeljanz, bad news continues to get worse. The increased chance of infection may be yet another risky side effect of Xeljanz, along with heart issues, blood clots, and cancer, according to a new study published last week. According to research published in the Annals of Rheumatic Diseases, Xeljanz infection risks were twice as high as those of substitute medications.

The study also found that patients taking the drug had an 87 percent higher risk of serious infection. Xeljanz, taken orally in tablet form, is used to treat rheumatoid arthritis and has been linked to increased risks of blood clots, heart failure and cancer since it was approved by the FDA in 2012. It is marketed by Pfizer Inc., which said it believes its product is safe when used as directed. These findings are yet another blow for people using this medicine, who are already at a higher risk for developing these infections due to the underlying condition they suffer from (rheumatoid arthritis).

July 2022 saw several new developments concerning Xeljanz lawsuits. In the U.S., a number of personal injury cases were filed in multiple states, including New Jersey and California. Plaintiffs claim that they suffered serious health complications related to the use of Xeljanz, with symptoms ranging from stroke, gastrointestinal bleeding, pulmonary embolism, liver failure and renal failure. 

In addition, several class action lawsuits were also filed against Pfizer Inc., the manufacturer of Xeljanz. These cases are affirming negligence on behalf of Pfizer for failing to adequately warn patients about the  risks associated with taking this drug. The plaintiffs further claim that Pfizer failed to take appropriate action to inform healthcare providers and consumers about the serious side effects. 

In Europe, the European Medicines Agency has also issued a safety alert concerning Xeljanz, citing  risks of developing serious infections and malignancies with use of this drug. The EMA is now recommending that only patients who cannot find an alternative treatment should be prescribed Xeljanz.

The month of June 2022 has seen a steady rise in Xeljanz lawsuits across the United States, with many plaintiffs affirming that they have suffered severe and life-threatening side effects due to their exposure to the medication. As of June 30, 2022, there are now 1,561 active Xeljanz lawsuits filed in state and federal courts throughout the country. 

At least 170 cases have been consolidated as part of an MDL (multi-district litigation) in the Northern District of California before District Judge Jeffrey White. The MDL is In re: Xeljanz (Tofacitinib Citrate) Products Liability Litigation No. 3:19-md-02920 JSW. The MDL is proceeding with discovery, and the court has set a November 2021 date for the first bellwether trials in which verdicts will be rendered. 

Meanwhile, in state courts throughout the country, individual Xeljanz lawsuits continue to make progress. Several cases have been filed against drug manufacturers Pfizer Inc., Incyte Corporation and Merck Sharp & Dohme Corp. in California, Florida and Pennsylvania respectively. Plaintiffs affirm that they suffered severe side effects such as stroke, pulmonary embolism, congestive heart failure, lymphoma and other blood cancers due to their use of the medication. Plaintiffs are seeking compensatory damages for medical expenses incurred due to these side effects as well as punitive damages related to product liability claims. 

These developments reflect the growing trend in Xeljanz lawsuits, and attorneys continue to expect the number of cases to rise as more people become aware of the  risks associated with taking this medication.

As of 2022, there are over 2,400 Xeljanz lawsuits pending in the U.S. District Court for the Northern District of California or in state courts around the country. These lawsuits were filed by individuals who developed pulmonary embolism after taking Xeljanz and affirm that Pfizer Inc., the manufacturer of Xeljanz, failed to adequately warn patients about  risks associated with this medication. Plaintiffs also accuse Pfizer of downplaying serious side effect warnings and promoting off-label uses for Xeljanz despite knowing that these indications could pose a risk to their health.

The first bellwether trials have been set for June 2022 in federal court and July 2022 in state court in California. Both trials are expected to be completed by the end of 2022. In addition, discovery is continuing in many cases, with both Pfizer and plaintiffs’ attorneys amassing evidence and preparing for trial.

The U.S. Food and Drug Administration (FDA) has directed Pfizer to update its drug label with more explicit warnings about  pulmonary embolism risks associated with Xeljanz use. The FDA also requested that a “boxed warning” be placed on the drug packaging itself to further inform consumers about the risks of taking this medication.

At present, the number of Xeljanz lawsuits continues to grow as more individuals come forward claiming their pulmonary embolism was caused by using Xeljanz. Our lawyers believe that this litigation could be the largest pharmaceutical-related case to date, with thousands of individuals  eligible for compensation. 

No Xeljanz lawsuit settlements have been made as of 2022, however some claimants are reportedly evaluating Pfizer compensation offers. In light of the fact that both parties are still preparing for trial, it is uncertain which of these offers will be accepted. Additionally, talks between the two parties are still going on and, if a deal can be achieved, result in a global settlement.

The outcome of the upcoming bellwether trials will likely set the tone for future claims against Pfizer regarding Xeljanz pulmonary embolism risks. Until then, it remains to be seen what the future holds for these litigations

Plaintiffs’ attorneys contend that Pfizer breached its obligation to protect its clients by failing to give sufficient warnings and information about the risks associated with the medicine. They think that before making Xeljanz available to the public, the corporation ought to have taken additional steps to guarantee that medication was secure for patients.

Pfizer and plaintiffs’ lawyers are actively negotiating a number of settlements. The first settlement agreement will open the door to further remedies in other cases and is anticipated to be finalized soon. After all is said and done, these agreements may be worth millions of dollars.

Patients are expecting that justice will be done as the amount of cases against Pfizer rises. Anyone considering legal action against the corporation will likely have a better picture of what lies ahead after the impending settlement and other developments in the Xeljanz lawsuits from April.

The Xeljanz lawsuit plaintiffs’ case got stronger as a result of the medical literature. In a Mayo Clinic study, the use of Xeljanz and other tumor necrosis factor (TNF) inhibitors was associated with higher rates of cancer incidence and unfavorable cardiovascular events (Remicade, Humira, Enbrel).

In March 2022, plaintiffs in the ongoing multi-district litigation (MDL) against Pfizer affirming injury due to the prescription rheumatoid arthritis drug Xeljanz are awaiting a decision on whether the case will be certified for trial. The federal judge presiding over the MDL is evaluating briefs submitted by both sides and will likely decide within the next few months. As of now, approximately 1,000 lawsuits have been filed as part of this litigation process – an increase from 500 since February 2021. 

Meanwhile, other legal actions related to Xeljanz continue to develop across the US. In Georgia, six separate cases have been consolidated into one lawsuit that claims the drug caused serious side effects, including life-threatening blood clots and malignant tumors. The plaintiffs have requested that their case be certified as a mass tort, with trial proceedings scheduled to take place in late 2022. 

Additionally, those who are injured due to Xeljanz seek out individual legal action against the manufacturers of this drug. Although some cases have already gone to trial, many more are currently pending in various locations across the country. Plaintiffs continue to affirm medical expenses, lost wages, and pain and suffering related to Xeljanz-related injuries. 

In conclusion, litigation regarding Xeljanz continues to develop as more individuals come forward with allegations of injury caused by this prescription medication. MDL proceedings remain in limbo, awaiting a decision from the federal judge, while other legal actions such as mass tort and individual litigation continue apace.

February 2022 saw further developments in the Xeljanz lawsuits, with a new lawsuit being filed by an Alabama resident who claims to have developed blood clots after taking Xeljanz. The case is currently ongoing and has been referred to U.S District Judge Abdul Kallon for management. In other developments, two plaintiffs previously dismissed due to a lack of jurisdiction refiled their cases in federal court citing increased evidence related to Pfizer’s failure to warn of the  risks associated with taking Xeljanz. Also, a ruling from the Missouri Eastern District Court granted permission for discovery into documents relating to the development and testing of Xeljanz as well as communications between Pfizer and the FDA. 

The surge in lawsuits during the month of February brought the total number of Xeljanz lawsuits up to over 375, with many more expected to follow. Pfizer recently announced it is setting aside $850 million for Xeljanz-related litigation, with some analysts predicting that this reserve will not be enough if current trends continue.

Overall, plaintiffs affirm that Pfizer either downplayed or failed to properly warn patients of the risks associated with taking Xeljanz and as such are seeking damages for related medical costs, permanent injury or disability, lost wages, and pain and suffering.

Drugmaker Pfizer continues to face mounting pressure on multiple fronts regarding the  side effects caused by its blockbuster rheumatoid arthritis drug Xeljanz. It remains to be seen if the company will be able to contain the growing number of lawsuits, or if it will have to increase its legal reserve even further. 

The February 2022 update also saw a new development in the Xeljanz multidistrict litigation (MDL), which was established in late 2019 for all federally-filed cases with similar allegations. On February 11th, U.S District Judge Claire C. Cecchi ordered Pfizer to produce non-public documents related to their internal communications about Xeljanz as part of a discovery process requested by plaintiffs. The ruling is expected to provide more evidence into Pfizer’s marketing and promotional practices relating to Xeljanz and lead to further legal steps in the future. 

The Xeljanz lawsuit landscape will remain one to watch throughout 2022, as the number of lawsuits filed continues to increase and plaintiffs seek justice for their affirmed injuries. It remains to be seen how Pfizer will respond to these mounting pressures. 

 As of now, the company continues to deny any wrongdoing.

More than 3,000 lawsuits have been filed against Pfizer Inc., the company that makes Xeljanz, by patients who claim the medication’s side effects cost them their lives. They include an elevated risk of heart attack, stroke, and pulmonary embolism. The Court of Common Pleas in Philadelphia has set a bellwether trial for March 15, 2022 to decide whether or not Pfizer will be held accountable for any harm the plaintiff may have sustained as a result of using Xeljanz. In addition, Pfizer has started making case-by-case compensation offers ranging from $2,500 to $25,000. When someone accepts such an offer, they give up the chance to sue the business afterwards. The court is keenly monitoring this trial and these settlement proposals because they could have a significant influence on any future agreements in the Xeljanz lawsuit.

News & Articles

The Dark Side of Xeljanz: Unveiling the Hidden Health Risks and How a Mass Tort Battle Seeks Justice

Unmasking the Power of Contingent Fee Lawyers: Your Unexpected Savior in Mass Torts Injury Cases

Xeljanz: A Cure or a Curse?

Manufactured by Pfizer, Xeljanz, also known as Tofacitinib, is a Janus kinase (JAK) inhibitor. It was approved by the FDA in 2012 as a treatment option for adults with moderate to severe active Rheumatoid Arthritis (RA). Subsequently, its usage was extended to Psoriatic Arthritis (PsA) and Ulcerative Colitis (UC). However, reports and studies have raised concerns about the drug's safety, leading to a mass tort case that questions whether Xeljanz is more of a cure or a curse?

A 2019 safety clinical trial conducted by Pfizer revealed that RA patients aged 50 years and above with at least one cardiovascular risk factor, who were administered a 10 mg dose of Xeljanz twice a day, had an increased risk of developing serious heart-related events and cancers compared to those on TNF blockers. The FDA consequently issued a warning in 2019 about the potential risks, demanding a black box warning, the strictest label warning.

Cardiovascular Complications: A Ticking Time Bomb?

One of the most alarming alleged side effects of Xeljanz is the purported connection with major cardiovascular events. It’s reported that patients taking this medication may face an increased risk of suffering heart attacks and strokes.

  • The safety clinical trial revealed a higher occurrence of cardiovascular events, including heart attacks and strokes, in patients treated with a 10mg twice-daily dose of Xeljanz than in those treated with a TNF blocker.
  • Reports from the FDA's Adverse Events Reporting System (FAERS) also suggested a possible linkage between Xeljanz and cardiovascular problems.

The exact reason for this increased risk isn't clearly understood yet. Some researchers speculate that JAK inhibitors like Xeljanz might interfere with the function of blood cells and platelets, contributing to clot formation. This leads to the question: Is Xeljanz a ticking time bomb, silently causing damage to the cardiovascular system?

Blood Clots and Beyond: Xeljanz's Other Hidden Dangers

Beyond cardiovascular complications, Xeljanz is reportedly associated with other serious health risks, notably pulmonary embolism (PE) and deep vein thrombosis (DVT).

  • PE, a condition where a blood clot lodges in the lungs, is potentially life-threatening. In the 2019 safety clinical trial, a statistically significant increase in PE was observed in patients taking a 10 mg twice-daily dose of Xeljanz compared to those on TNF blockers.
  • DVT, a condition where blood clots form in the deep veins, usually in the legs, can lead to PE if the clots travel to the lungs. The risk of DVT is also reportedly increased in Xeljanz patients.

In addition to these, patients have reported a range of other health-related side effects, including vision problems, intestinal disorders, and varying forms of cancers. Taken together, these reports raise serious concerns about the safety profile of Xeljanz, adding weight to the ongoing mass tort and the question around its alleged hidden dangers.

Lawsuit Help Desk: A Lifeline for Victims

In the face of the alleged dangers associated with Xeljanz, where can victims turn for help? Enter the Lawsuit Help Desk, a beacon of hope and support for those affected. The Lawsuit Help Desk is a professional service that connects victims of alleged pharmaceutical negligence with leading law firms that specialize in mass tort cases.

  • The Lawsuit Help Desk operates as a bridge between victims and legal representation. Their mission is to ensure that every victim has a chance to seek justice and hold manufacturers accountable for the alleged harm caused by drugs like Xeljanz.
  • Victims seeking guidance and support from the Lawsuit Help Desk can expect comprehensive assistance. This includes understanding the mass tort process, gathering necessary information, and connecting with legal practitioners equipped to handle their case.

It's worth noting that the Lawsuit Help Desk is not just an intermediary. They're advocates for public health awareness, aiming to shed light on the potential dangers of certain medications and medical devices. But could their efforts be enough to usher in change in corporate responsibility and healthcare regulation?

Fighting for Justice: The Battle for Compensation and Accountability

What's the ultimate goal of the Lawsuit Help Desk and the legal firms they associate with? Simply put, their mission is to fight for justice and secure financial compensation for those reportedly harmed by Xeljanz.

  • By providing victims with access to legal counsel, the Lawsuit Help Desk empowers individuals to take action against alleged negligence by pharmaceutical giants. The aim is to hold manufacturers accountable for the potential harms and negative health impacts associated with their products.
  • The pursuit of justice isn't just about financial compensation. It's about recognizing the potential harm done to patients and pushing for necessary changes in the pharmaceutical industry. Was the necessary due diligence exercised before Xeljanz came to market? Did the benefits truly outweigh the risks? Questions like these are central to mass tort cases and the pursuit of justice.
  • Another critical aspect of their mission is advocacy. By raising public awareness about potential pharmaceutical risks and corporate negligence, the Lawsuit Help Desk strives to protect future patients and promote a safer, more accountable healthcare system.

The battle is certainly an uphill one, with numerous cases pointing to a complex web of corporate interests, health risks, and regulatory oversights. Yet, the resolve of the victims, their families, and the legal teams representing them remains steadfast. For them, the fight for justice goes beyond the courtroom – it's about acknowledging the alleged damage caused by Xeljanz, supporting those affected, and ensuring that such a tragedy doesn't repeat.

The Xeljanz mass tort is much more than a legal battle. It's a call for change in the pharmaceutical industry, an advocacy for greater transparency, and a fight for justice for those who may have fallen victim to alleged corporate negligence. And as the battle rages on, one thing is clear: this fight is far from over.'s mission is to restore justice by finding every mass tort victim leading litigation counsel. Our services are free! We're also the leading information portal for people who have been injured from mass torts. We'd love to hear from you!

FDA’s Oversight of Xeljanz

In this article, we give a general summary of the FDA’s monitoring and oversight of Xeljanz in this post, covering the necessary testing and clinical studies, any warnings issued, findings attained, and other actions done, as well as any warnings.

Observation and Supervision

The drug Xeljanz is used to treat a number of autoimmune diseases. These conditions include ulcerative colitis and rheumatoid arthritis. Xeljanz underwent extensive research and clinical trials to make sure it was safe and effective for use in patients, much like all new medications that sought FDA clearance. However, serious safety risks have been uncovered.

Mandatory Testing

Like any new drug, Xeljanz was required to must pass multiple stages of testing to show that it is both safe and effective before the FDA was willing to approve it. These phases for Xeljanz included three phases of human clinical trials as well as preclinical research on animals.

The purpose of the clinical studies for Xeljanz, which involved thousands of patients, was to assess the drug’s safety and efficacy at various doses and in various patient populations. Trials evaluated potential adverse effects and medication interactions as well.

Mandatory Clinical Trials

There were three stages of the Xeljanz clinical trials: Phase 1: To ascertain the drug’s safety and pharmacokinetics, a small group of healthy volunteers were administered various doses of the medication. Phase 2: More patients with the targeted autoimmune condition were involved in this phase. This phase’s objective was to assess the drug’s efficacy and safety at various dosages. Phase 3: Patients with the specific autoimmune condition were involved in even bigger groups in this phase. This phase’s objective was to confirm the medication’s efficacy and safety over a larger patient base.

Warnings are given

The FDA issued many safety-related warnings following the approval of Xeljanz. The FDA issued a warning in February 2019 regarding an elevated risk of blood clots and fatalities in individuals taking higher dosages of Xeljanz. Because to this caution, the drug’s label was altered to add a black box warning concerning the elevated risk of blood clots.

The FDA again issued a warning in July 2021 regarding individuals on Xeljanz at a dose of 10 mg twice daily having an elevated risk of fatal heart-related events, cancer, and other adverse events. The FDA advised using Xeljanz at the lowest effective dose in all patients and not prescribing it to people who had specific underlying illnesses, such as heart disease.

Additional Steps Taken

The FDA has taken further measures in relation to Xeljanz in addition to the warnings that it has published. For instance, the FDA mandated that Pfizer carry out a post-marketing study to further assess the hazards connected to the medication. This investigation is still underway and will offer further information regarding the security of Xeljanz in practical situations. Also, the FDA mandates that Pfizer continuously monitor Xeljanz’s safety and notify the organization of any fresh safety concerns. This monitoring is meant to address drug safety concerns and ensure issues are found and resolved quickly.


Due to the serious potential complications of certain autoimmune disorders, doctors have been authorized to keep prescribing Xeljanz despite its associated risks. Clinical trials have proven beneficial results in terms of symptom relief and quality of life improvement for people afflicted with a variety of conditions. As such, healthcare practitioners must ensure that patients are aware of the dangers linked to this particular medication while also using the lowest effective dosage. Furthermore, all patients taking Xeljanz should be closely monitored for signs of blood clots, heart-related incidents or any other adverse reactions.

The large number of lawsuits filed for blood clots and heart conditions from Xeljanz usage is indicative of the life-threatening implications of its usage. 

PAID ATTORNEY ADVERTISEMENT: This Website is a group advertisement. It is not a lawyer referral service. is owned and operated by Awon Holdings LLC and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. Results are not guaranteed and past performance is not an indication of future success. Always consult with your doctor before modifying your medication or regular medical regimen.

Copyright © 2023 - All Rights Reserved